ImmunityBio, Inc. - 8-K Filing
FDA expands ANKTIVA approval for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) to include patients with papillary-only tumors. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $IBRX
Read the full article at SEC EDGAR
Part of the story FDA Expands Approval of ImmunityBio's Anktiva to Include Early-Stage Bladder Cancer (2 articles)